Advertisements

Торасемид-СЗ

Quick links to important sections

Торасемид-СЗ

Selected form

Advertisements
Advertisements

Method of action: Diuretic

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Торасемид-СЗ

What is Торасемид-СЗ? (Torasemide)

Property Description
Active ingredient Torasemide (INN)
Form Oral tablets (e.g., film-coated tablets)
Pharmacological class High-ceiling Diuretic (Loop Diuretic)
Common purpose Managing excess fluid and supporting fluid balance
Origin Synthetic, Sulfonamide derivative

What Type of Medicine is Торасемид-СЗ? (Identity and Classification)

Торасемид-СЗ is a specific commercial preparation of the active substance Torasemide (INN), a synthetic, single-component pharmaceutical agent. This medicine is formally classified as a high-ceiling diuretic, which belongs to the functional group of loop diuretics. Torasemide is a sulfonamide derivative. This pharmacological classification is clinically recognized for its potent action on renal function, setting it apart from milder agents. As a prescription drug, the use of Торасемид-СЗ is reserved for situations where strong systemic fluid volume control is medically indicated.

Composition and Physical Form of Торасемид-СЗ (Form and Composition)

The standard dosage form for Торасемид-СЗ is the oral tablet, often finished with a film coating. This format facilitates convenient and non-invasive oral administration. The composition is based on the active substance, Torasemide, combined with necessary solid pharmaceutical excipients that form the tablet matrix. Torasemide is characterized by high bioavailability when delivered orally, indicating that a substantial amount of the drug is available to exert its intended effect, which is a critical differentiating factor in its management profile.

What is the General Purpose of Torasemide? (High-Level Benefit)

The fundamental purpose of Torasemide is to restore fluid balance by effectively enhancing the renal excretion of both sodium and water. Its primary functional effect is to promote pronounced diuresis, resulting in a substantial increase in urine output. This powerful action is utilized in physiological scenarios involving fluid overload, such as excess fluid retention in tissues. This high-efficacy diuresis helps rapidly reduce the total fluid volume circulating in the body.

Regulatory References

  1. Loop Diuretics Overview
  2. Physiology of Kidney Function
Advertisements

What side effects are possible with Торасемид-СЗ?

Possible side effects and safety information

Torasemide's official safety profile is primarily characterized by effects related to its potent diuretic action on fluid and electrolyte balance, as documented by regulatory agencies such as the FDA and the EMA.

Adverse reactions are classified by frequency and categorized into System-Organ-Classes (SOC).

Classification Scope Examples based on Regulatory Documents
Common Effects Headache, dizziness, fatigue, and gastrointestinal disturbances. The most frequently noted metabolic effects are hypokalemia (low potassium) and hypovolemia (volume depletion).
Uncommon Effects Vertigo, paresthesia (tingling/numbness), and increases in laboratory markers like blood urea and creatinine.
System-Organ Classes Effects are grouped across systems including Metabolism and Nutrition Disorders, Nervous System Disorders, Gastrointestinal Disorders, and Renal and Urinary Disorders.

Serious Adverse Reactions and Safety Constraints

The regulatory labels identify several clinically significant outcomes. These include the potential for Acute Renal Failure and severe Hypotension. For individuals with severe hepatic impairment, changes in fluid and electrolyte balance may precipitate hepatic coma; this is a key population-specific safety concern noted in the prescribing information.

Regulatory documentation also defines explicit contraindications, specifying that Torasemide must not be used in patients with anuria (absence of urine production) or pre-existing severe conditions like hypovolemia or hyponatremia (low sodium levels). The risk of certain side effects, such as gastrointestinal disturbances, may be more pronounced at the start of treatment.

Advertisements

Overdose and Emergency Response

Officially Documented Overdose Manifestations

Overdose with Торасемид-СЗ (Torasemide) is formally documented in regulatory sources as leading to excessive diuresis and acute volume depletion. The documented clinical manifestations resulting from this loss include profound hypotension (severely low blood pressure), dehydration, and hypovolemia. Signs of severe electrolyte imbalance, such as hypokalemia and hyponatremia, may present as confusion, somnolence, muscle cramps, and pronounced weakness. Laboratory findings commonly include metabolic alkalosis.

Severe Outcomes and When to Seek Urgent Help

Immediate medical attention must be sought upon any suspicion of overdose or if the following severe outcomes manifest: circulatory collapse, acute renal failure, or cardiac arrhythmias. Regulatory labels note that in patients with existing hepatic disease, overdose may precipitate a hepatic coma. For elderly patients, regulatory information highlights an increased risk of thrombosis and embolism due to excessive volume reduction.

Mandated Emergency Actions

Management is strictly symptomatic and supportive. Regulatory guidance mandates immediate drug discontinuation and subsequent procedural correction of fluid and electrolyte imbalances through intravenous fluids and replacement of lost electrolytes. It is officially stated that no specific antidote is known for Torasemide overdose.

Advertisements

Therapeutic Uses of Торасемид-СЗ

What Торасемид-СЗ Treats: Main Uses and Benefits

This medication is commonly used for managing symptoms related to systemic imbalance and fluid overload that arise in several major conditions. The application of Торасемид-СЗ occurs across domains where additional symptomatic support is needed, relevant in conditions characterized by periods of heightened symptoms.

It is commonly used across conditions characterized by periods of heightened symptoms, including the supportive management of edema (swelling) associated with Congestive Heart Failure (CHF), Chronic Kidney Disease, and Liver Cirrhosis, as well as contributing to the management of volume-related High Blood Pressure (Hypertension).

In these contexts, the medicine is relevant for easing symptoms related to physical discomfort, such as those that characterize fluid collections like Ascites and generalized tissue swelling. Managing this chronic systemic imbalance helps maintain a sense of stability when symptoms are more noticeable.

“Managing symptoms related to systemic imbalance is often relevant in clinical settings that involve acute or unstable symptom patterns.”


Quick Fact: Focus on Fluid Management and Swelling

Торасемид-СЗ provides support that helps ease the overall symptom burden of fluid retention, assisting with maintaining functional stability and supporting patients during episodes of heightened discomfort.

Regulatory References

  1. DailyMed official drug label overview
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Торасемид-СЗ (Torasemide) — Official Regulatory Information

Official regulatory documents define strict eligibility criteria and contraindications for Torasemide-SZ, primarily restricting its use to adult patients who do not have certain severe pre-existing conditions.

Eligibility Status Populations & Conditions (Must Not Use)
Absolute Contraindication Known hypersensitivity to torasemide or to sulfonylureas (sulfa-drugs).
Anuria (inability to produce urine) due to renal failure.
Hepatic coma and pre-coma.
Severe hypovolemia (low blood volume) or hypotension (low blood pressure).
Pregnancy and lactation (by several government bodies).
Restricted/Not Established Children and Adolescents (typically under 18 years) due to lack of established safety and efficacy data.
Patients with hepatic disease (e.g., cirrhosis with ascites) require extreme caution, as sudden fluid shifts may precipitate hepatic coma.
Uncorrected pronounced fluid-electrolyte imbalances, such as severe hypokalemia.

Use is highly conditional on the absence of these life-threatening organ complications and severe imbalances. Use in the pediatric population is not recommended, and it is largely prohibited during pregnancy and breastfeeding based on official regulatory labeling.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Torasemide-SZ based on pharmacokinetic, pharmacodynamic, and absorption interference patterns. Combination with medicines containing sulfonylureas is a formal restriction noted in regulatory labeling due to documented hypersensitivity risk.


Pharmacokinetic and Exposure Alterations

Torasemide clearance is subject to CYP2C9 metabolic pathways. Co-administration with CYP2C9 Inhibitors (e.g., fluconazole) may increase Torasemide plasma concentrations, whereas CYP2C9 Inducers (e.g., rifampin) may cause a decrease in exposure. Torasemide may affect the safety profile of sensitive CYP2C9 substrates like warfarin. Separately, co-administration with Digoxin is reported to increase Torasemide's total exposure (AUC) by fifty percent.

Pharmacodynamic and Timing Constraints

Non-steroidal Anti-inflammatory Drugs (NSAIDs) are associated with reduced diuretic effects and an increased risk of renal impairment. Co-administration with Renin-Angiotensin Inhibitors (e.g., ACE inhibitors) increases the risk of hypotension and renal impairment. Use with Corticosteroids is associated with an increased risk of hypokalemia (low potassium). The label explicitly requires that Torasemide administration be separated by time from the administration of Cholestyramine to mitigate absorption interference. Furthermore, the label notes that simultaneous consumption of alcohol may increase the risk of dizziness or low blood pressure.

Advertisements

Mechanism of Action

Inhibiting Electrolyte Transport in the Renal System

Торасемид acts as a direct inhibitor of the Na^+/ K^+/2 Cl^- cotransporter (NKCC2), the primary electrolyte pump located on the luminal side of the thick ascending limb of the loop of Henle. By blocking the reabsorption of sodium, potassium, and chloride ions from the forming urine, the mechanism creates a strong osmotic gradient that retains large amounts of water in the renal tubules, initiating significant Na^+/ Cl^- excretion (natriuresis) and diuresis.

Systemic Fluid Dynamics and Hemodynamic Effect

The resulting reduction in sodium and water volume within the circulatory system is the immediate systemic consequence of the renal blockade. This physiological change induces systemic fluid volume reduction, which lowers the intravascular pressure and vascular resistance. The mechanism thus adjusts systemic fluid dynamics by regulating circulatory volume.

Modulation of Aldosterone-Related Pathways

The drug’s mechanism includes modulation of the Renin-Angiotensin-Aldosterone System (RAAS), leading to reduced aldosterone exposure. This action influences signaling pathways associated with tissue stiffness and myocardial collagen deposition. This modulatory effect acts on pathways that regulate cardiac tissue structure.

Advertisements

Dosage and Administration Information

Instructions for Using Торасемид-СЗ

These guidelines outline the procedure for using this medication.

Administration Scope Requirement
Route of Administration Oral (by mouth)
Dosing Frequency Once daily
Timing with Food May be administered without regard to meals

Procedural Dosing Rules

Therapy is typically initiated at a low, specified starting dose, such as 5 mg to 20 mg once daily, depending on the condition being addressed. If the initial diuretic response is insufficient, the daily dose may be adjusted upwards by approximately doubling the amount until the desired response is observed. The guidelines state that doses higher than 200 mg have not been adequately studied for most conditions, and doses above 40 mg are not recommended for patients with hepatic cirrhosis.

Special Administration Conditions

  • Drug Interaction Timing: If co-administering with the bile acid sequestrant cholestyramine, the medication must be taken at least 1 hour before or 4 to 6 hours after the cholestyramine dose to ensure proper absorption and effectiveness.
  • Hepatic Cirrhosis: When treating edema associated with hepatic cirrhosis, the initial dose is administered concomitantly with an aldosterone antagonist or a potassium-sparing diuretic.

Missed Dose

If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the patient should return to the regular dosing schedule. Double doses should not be taken to make up for a missed dose.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Торасемид-СЗ

The research on the active ingredient in Торасемид-СЗ, Torasemide, was studied for use in contexts involving excess fluid in several chronic conditions. These studies are designed to observe patterns of change and measured effects in groups of people, helping to build an understanding of how the medicine was observed in a clinical setting. Research does not determine whether an individual will respond similarly; findings describe group patterns, not personal outcomes.


Evidence for Use in Managing Fluid Overload in Heart Failure (CHF Edema)

The evidence base for Torasemide in contexts involving heart failure-related fluid imbalance, which can cause swelling (edema), includes a broad range of study types. This research has included Randomized Controlled Trials (RCTs) and large pragmatic trials. Researchers studied outcomes related to physical discomfort and systemic imbalance by tracking measured endpoints such as all-cause mortality, the frequency of hospital admissions were tracked, and changes in functional status and activity level.

However, when examining Torasemide against other diuretics for long-term clinical endpoints like all-cause mortality and overall hospitalization rates, studies reported differing patterns across the largest trials. This means that while research provides insight into short-term fluid management, it is not yet clear whether a measurable difference exists in long-term outcomes. Data are still emerging, and long-term effects are not fully established for all subgroups.


Evidence for Use in Managing Fluid Retention Linked to Chronic Kidney Disease (CKD Edema)

Torasemide was also evaluated in clinical and comparative studies involving adults who have fluid retention due to chronic kidney disease. Research explored changes on the kidneys' ability to excrete sodium and water, known as the diuretic and natriuretic response. Studies focused on outcomes reflecting temporary physiological imbalance, such as short-term urine output, and monitored changes in blood pressure and markers of kidney function.

A key limitation here is that many of these studies had modest sample sizes and the follow-up durations were limited. This means the research provides limited insight into long-term outcomes for patients with CKD, and data for certain groups remain insufficient.


What is Still Uncertain About the Research on Торасемид-СЗ

An honest look at the evidence highlights several limitations and areas where certainty remains low. One key uncertainty stems from the mixed findings reported across the largest comparative trials for long-term outcomes in heart failure. Furthermore, a significant limitation is that follow-up durations were limited in many studies, especially for kidney and liver edema and for chronic blood pressure management. This means there is limited information for long-term outcomes and the persistence of any observed response over many years. For certain complex patient groups or specific severities of disease, data remain insufficient.

Key Studies & References

  1. Torsemide - StatPearls (for general indications, dosing and pharmacology)
  2. Label: DEMADEX (torsemide) tablet - Official Drug Label (DailyMed)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Торасемид-СЗ (FAQ)

Q: How quickly should I expect Торасемид-СЗ to start working?

According to official regulatory documents, the initial increase in urination (diuresis) from Torasemide tablets generally begins within one hour of administration. The strongest effect is typically observed during the first or second hour after the dose is taken.


Q: How long do the effects of one dose of Торасемид-СЗ typically last?

Official product information indicates that the diuretic effect of a single oral dose usually lasts for approximately six to eight hours.


Q: Is it okay to take Торасемид-СЗ if I also take a vitamin supplement?

The use of loop diuretics may be associated with the loss of certain electrolytes and nutrients, including potassium, magnesium, folic acid, and Vitamin B1. For this reason, monitoring of nutrient levels is often recommended in official documents when considering long-term therapy.


Q: Is Торасемид-СЗ safe for older adults or elderly people?

Official information notes that older adults may metabolize the drug more slowly, which can result in higher concentrations in the body. Therefore, the official information notes that a lower starting dosage or a modified administration schedule is often considered for this population.


Q: Can Торасемид-СЗ affect my sleep patterns?

Yes, official adverse event reports indicate that insomnia (difficulty sleeping) and nervousness are listed among the common side effects of the medication.


Q: Are there specific symptoms that mean I should stop taking Торасемид-СЗ?

Signs of fluid or electrolyte imbalance, such as extreme dry mouth, severe thirst, muscle pains or cramps, weakness, or an irregular heartbeat (arrhythmia), are symptoms that official documents state warrant prompt communication with a healthcare professional. These symptoms may indicate potentially severe volume depletion.


Q: Can Торасемид-СЗ affect blood sugar levels in people without diabetes?

Studies indicate that treatment with Torasemide can be associated with an increase in blood glucose levels. This metabolic change may potentially lead to a condition known as hyperglycemia.


Q: Is Торасемид-СЗ usually taken in the morning or at night?

To prevent night-time urination (nocturia) from interfering with sleep, official guidance often suggests scheduling administration to avoid taking the drug within approximately four hours of bedtime.


Q: What should I do if I experience dry mouth while on Торасемид-СЗ?

Dry mouth and increased thirst are listed in official safety documents as common signs of potential volume depletion or electrolyte imbalance. These are symptoms that official safety documents state warrant prompt communication with a healthcare professional for evaluation.


Q: Are there any reported interactions between Торасемид-СЗ and herbal supplements?

Official documents state that caution is warranted with herbal supplements that have a diuretic effect, such as juniper, as they may enhance the drug's action. Additionally, some substances like licorice may worsen potassium loss when combined with Torasemide.


Q: Is it necessary to drink extra water when taking Торасемид-СЗ?

Official guidance emphasizes maintaining adequate fluid intake to prevent dehydration or excessive volume depletion. This general recommendation is made unless a healthcare professional has specifically directed a restriction on fluid intake.


Q: Does Торасемид-СЗ have a known impact on cholesterol levels?

The medication has been associated with small, temporary increases in total plasma cholesterol and plasma triglycerides in short-term studies. These types of laboratory changes often subside during chronic therapy.


Q: Can Торасемид-СЗ be stopped suddenly, or does it need to be tapered?

Official regulatory information indicates that if Torasemide administration is suddenly discontinued, blood pressure typically returns to pre-treatment levels over several days without any immediate rebound effect.


Q: Does Торасемид-СЗ affect magnesium levels in the body?

Regulatory documents note that Torasemide can cause hypomagnesemia (low magnesium levels), which is a potential electrolyte abnormality. For this reason, official safety information notes that periodic monitoring of serum electrolytes is a necessary measure.


Q: Is it possible for Торасемид-СЗ to cause temporary hearing changes?

Tinnitus (ringing in the ears) and hearing loss have been observed with loop diuretics, including Torasemide. Official warnings note that this effect is usually described as reversible.


Q: Is Торасемид-СЗ ever prescribed for people with high blood pressure but no fluid retention?

Yes, according to FDA labeling, Torasemide is officially indicated for the treatment of hypertension (high blood pressure) to help achieve lower blood pressure levels.


Q: Does Торасемид-СЗ affect uric acid levels?

Official safety information indicates that Torasemide may cause asymptomatic hyperuricemia, meaning elevated uric acid in the blood. In rare instances, this metabolic change may precipitate gout.

Advertisements

How should Торасемид-СЗ be stored and disposed of?

Storage and Disposal Instructions for Torasemide Tablets

Torasemide tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be maintained in a closed container and protected from excessive heat, moisture, and direct light. It is mandatory that the tablets not be frozen.

Protection and Handling

Storage Requirement Condition
Temperature Controlled Room Temperature
Environment Protect from Heat, Moisture, and Freezing
Safety Keep out of the reach of children

Disposal of Unused Product

Unused or expired Torasemide tablets should be properly discarded by consulting a healthcare professional or local waste authority for guidance. Officially, unused medicine must not be kept. Non-flush list drugs should be mixed with an undesirable substance and sealed for safe disposal in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Торасемид-СЗ found in:

A-Z Index: